Nymox Pharmaceutical Corporation announced a Special Shareholder Meeting scheduled for August 28, 2026, to elect five directors to its Board of Directors. The company currently has two directors and proposes expanding the board to five members, with nominees including CEO Paul Averback, David Morse, Kresimir Pucaj, Russell Thomson, and Robert Lachance. Voting rights are determined by a record date of August 4, 2026, for approximately 105 million outstanding common shares. The filing also notes that the annual report on Form 20-F for the fiscal year ended December 31, 2025, has been delayed due to previous changes in management and the board. Nymox Pharmaceutical Corporation operates in the pharmaceutical industry, focusing on drug discovery and development.